Log in to your Inderes Free account to see all free content on this page.
Create account

Elicera Therapeutics

3.25 SEK

-2.99 %

Less than 1K followers

ELIC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

-2.99 %
-38.54 %
-42.05 %
-37.84 %
-47.91 %
-4.28 %
-10.11 %
-
-47.66 %

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.

Read more
Market cap
157.5M SEK
Turnover
415.43K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.5.
2026

General meeting '26

5.5.
2026

Interim report Q1'26

8.5.
2026

Extraordinary general meeting '26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.